Drugs / LAS41003
last change Jul 2011 re-read 2 minutes ago

LAS41003

Developed for
candidiasis · dermatitis · tinea pedis
Investigated by
Almirall, S.A.

Trials 3 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01102387 Feb 2010 → Jul 2011 candidiasis Almirall, S.A. Completed No outcome recorded
Phase 2 NCT01096472 Feb → Jun 2010 tinea pedis Almirall, S.A. Completed No outcome recorded
Phase 2 NCT01020994 Nov 2009 → Jun 2010 dermatitis Almirall, S.A. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as LAS41003 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01102387
2

NCT01096472

NCT01020994

Route Topical “Once daily, topically” NCT01020994